DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis

Information source: EMD Serono
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Multiple Sclerosis

Intervention: Interferon-beta-1a FBS-free/HSA-free (Biological)

Phase: Phase 3

Status: Completed

Sponsored by: EMD Serono

Official(s) and/or principal investigator(s):
Bettina Stubinski, MD, Study Director, Affiliation: Merck Serono SA - Geneva


The primary objective of the study is to compare the immunogenicity of the new fetal bovine serum (FBS)-free/human serum albumin (HSA)-free Rebif« formulation (RNF) to historical data.

Clinical Details

Official title: A Multicentre, Single Arm, Open-Label, Phase IIIB Study to Evaluate the Safety and Antigenicity of Rebif« (Interferon-beta-1a) in Subjects With Relapsing Forms of Multiple Sclerosis

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Number of Participants Who Were Neutralising Antibody (NAb) Positive at the Week 96 Visit.

Secondary outcome:

Number of Participants Who Were Neutralising Antibody (NAb) Positive at Anytime During the Study

Number of Participants With Binding Antibodies (BAb) at Week 96

Detailed description: As has been seen with other recombinant protein molecules, the use of injectable recombinant proteins may result in the development of neutralising antibodies (NAbs). Antibodies are considered neutralising by their ability to inhibit the biological effect of interferon in a bioassay system. EMD Serono has actively pursued improvements in the formulation of interferon (IFN) beta-1a to reduce aggregate levels and to develop a formulation that is HSA-free. Reducing aggregates should reduce antigenicity of the product while removal of HSA may have an unpredictable effect on antigenicity. EMD Serono will conduct a study to assess the immunogenicity and safety of the new HSA-free formulation, manufactured using IFN-├č-1a drug substance produced by a new clone from the FBS-free process.


Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- Participant has a relapsing form of Multiple Sclerosis (MS); diagnosis of MS is in

accordance with the McDonald criteria

- Participant is eligible for interferon therapy

- Participant is between 18 and 60 years old

- Participant has an Expanded Disability Status Scale (EDSS) < 6. 0.

- Participant is willing to follow study procedures

- Participant has given written informed consent

- Female participants must be neither pregnant nor breast-feeding, and must lack

childbearing potential, as defined by either:

- Being post-menopausal or surgically sterile, or

- Using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide or

condom with spermicide for the duration of the study.

- Confirmation that the participant is not pregnant must be established by a negative

serum or urinary hCG test within 7 days prior to start of study treatment. A pregnancy test is not required if the participant is post-menopausal or surgically sterile. Exclusion Criteria:

- Participant has a Clinically Isolated Syndrome (CIS), Primary Progressive MS, or

Secondary Progressive MS without superimposed relapses.

- Participant had any prior interferon beta therapy (either beta-1b or beta-1a)

- Participant has an ongoing MS relapse.

- Participant received any other approved disease modifying therapy for MS (e. g.

glatiramer acetate) or any cytokine or anti-cytokine therapy within the 3 months prior to Study Day 1(SD1).

- Participant had prior use of cladribine or has previously received total lymphoid


- Participant received oral or systemic corticosteroids or adrenocorticotropic hormone

(ACTH) within 30 days of SD1.

- Participant received intravenous immunoglobulins or underwent plasmapheresis within

the 6 months prior to SD1.

- Participant received immunomodulatory or immunosuppressive therapy (including but not

limited to cyclophosphamide, cyclosporin, methotrexate, azathioprine, linomide, mitoxantrone, teriflunomide, natalizumab, laquinimod, Campath) within the 12 months prior to SD1.

- Participant requires chronic or monthly pulse corticosteroids during the study.

- Participant received any investigational drug or experimental procedure within 12

weeks of SD1.

- Participant has inadequate liver function, defined by a total bilirubin, aspartate

aminotransferase (AST) or alanine aminotransferase (ALT) or alkaline phosphatase > 2. 5 times the upper limit of the normal values.

- Participant has inadequate bone marrow reserve, defined as a white blood cell count

less than 0. 5 x lower limit of normal.

- Participant suffers from current autoimmune disease.

- Participant suffers from major medical or psychiatric illness that in the opinion of

the investigator creates undue risk to the subject or could affect compliance with the study protocol.

- Participant has a known allergy to IFN or the excipients.

Locations and Contacts

Local US Medical Information, Rockland, Massachusetts 02370, United States
Additional Information

Full FDA approved prescribing information can be found here

Starting date: January 2005
Last updated: June 18, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017